Activity of iclaprim against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae | Zendy

Ian Morrissey | Zendy; K. Maher | Zendy; Stephen Hawser | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Activity of iclaprim against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae

Author(s) -

Ian Morrissey,

K. Maher,

Stephen Hawser

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn505

Subject(s) - streptococcus agalactiae , streptococcus pyogenes , microbiology and biotechnology , streptococcus , biology , bacteria , staphylococcus aureus , genetics

miology of MRSA bacteraemia in the UK. J Antimicrob Chemother 2005; 56: 455–62. 7. Enright MC, Day NP, Davies CE et al. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000; 38: 1008–15. 8. Stefani S, Mezzatesta M, Trovato G et al. Antibacterial activity of PZ-601 against well-characterized and recent clinical isolates of methicillin-resistant Staphylococcus aureus. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract F1-231, p. 199. American Society for Microbiology, Washington, DC, USA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research